

AvMed

PHARMACY PRIOR AUTHORIZATION/STEP-EDIT REQUEST*

Directions: The prescribing physician must sign and clearly print name (preprinted stamps not valid) on this request. All other information may be filled in by office staff; **fax to 1-305-671-0200.** No additional phone calls will be necessary if all information (including phone and fax #s) on this form is correct. **If the information provided is not complete, correct, or legible, the authorization process can be delayed.**

Migraine Treatment: Injectable Calcitonin Gene-Related Peptide (CGRP) Antagonists

Drug Requested: (Select one from below)

PREFERRED	
<input type="checkbox"/> Aimovig® (erenumab)	<input type="checkbox"/> Emgality® (galcanezumab)
NON-PREFERRED	
<input type="checkbox"/> Ajovy® (fremanezumab) *Member must have tried and failed ALL preferred agents (including Nurtec ODT® and Qulipta™) and meet all PA criteria for approval of Ajovy*	

MEMBER & PRESCRIBER INFORMATION: Authorization may be delayed if incomplete.

Member Name: _____

Member AvMed #: _____ Date of Birth: _____

Prescriber Name: _____

Prescriber Signature: _____ Date: _____

Office Contact Name: _____

Phone Number: _____ Fax Number: _____

NPI #: _____

DRUG INFORMATION: Authorization may be delayed if incomplete.

Drug Name/Form/Strength: _____

Dosing Schedule: _____ Length of Therapy: _____

Diagnosis: _____ ICD Code, if applicable: _____

Weight (if applicable): _____ Date weight obtained: _____

- Will the member be discontinuing a previously prescribed injectable or oral calcitonin gene-related peptide (CGRP) antagonist medication if approved for requested medication?

Yes **OR** No

(Continued on next page)

PA Migraine Treatment: Injectable CGRP Antagonists (AvMed)
(Continued from previous page)

- If yes, please list the medication that will be discontinued and the medication that will be initiated upon approval along with the corresponding effective date.

Medication to be discontinued: _____ **Effective date:** _____

Medication to be initiated: _____ **Effective date:** _____

Recommended Dosing & Quantity Limits:

Drug	Dose	Quantity Limit
Aimovig® (erenumab)	<ul style="list-style-type: none"> Migraine Prophylaxis: Initial: 70 mg SC once a month; some members may benefit from 140 mg once a month (given as 2 consecutive 70 mg injections) 	<ul style="list-style-type: none"> 70 mg/mL (1 mL/30 day) 140 mg dose (2 mL/30 days) If using the 140 mg dose, must use the package labeled specifically for 140 mg/mL
Ajovy® (fremanezumab)	<ul style="list-style-type: none"> Migraine Prophylaxis for adults 18 years of age or older: 225 mg SC monthly or 675 mg every 3 months Migraine Prophylaxis for children ≥6 years and Adolescents ≤17 years, weighing ≥45 kg: 225 mg SC monthly 	<ul style="list-style-type: none"> 225 mg/1.5 mL; 1.5 mL (1 syringe) per 30 days or 4.5 mL (3 syringes) per 90 days
Emgality® (galcanezumab)	<ul style="list-style-type: none"> Migraine Prophylaxis: Initial: 240 mg SC as a single loading dose, followed by 120 mg once monthly Episodic cluster headache prophylaxis: 300 mg SC at the onset of the cluster period and then once monthly until the end of the cluster period 	<ul style="list-style-type: none"> 120 mg/mL; 1 mL (1 auto-injector and prefilled syringe) per 30 days with one time loading dose of 2 mL (2 auto-injectors) For Episodic Cluster headache diagnosis only: 300 mg dose; 100 mg/mL prefilled syringe

CLINICAL CRITERIA: Check below all that apply. All criteria must be met for approval. To support each line checked, all documentation, including lab results, diagnostics, and/or chart notes, must be provided or request may be denied.

Authorization Criteria

- Member must meet **ONE** of the following age requirements:
 - For Aimovig & Emgality requests:** Member must be 18 years of age or older
 - For Ajovy requests:** Member must be 6 years of age or older and weigh 45 kg or more
- Provider has attested to all clinical criteria for **ONE** of the applicable diagnoses below

DIAGNOSIS: Please check **ONE** of the applicable diagnoses below

- Chronic & Episodic Migraine Headache Prevention** (All applicable boxes below must be met to qualify)

(Continued on next page)

PA Migraine Treatment: Injectable CGRP Antagonists (AvMed)
(Continued from previous page)

- ❑ Member must have a diagnosis of Chronic or Episodic Migraine Headache defined by **BOTH** of the following:
 - ❑ Member has ≥ 4 migraine headache days per month
 - ❑ Member must have failed a **2-month** trial of at least one medication from **TWO** different migraine prophylactic classes supported by the American Headache Society/American Academy of Neurology treatment guidelines 2012/2015/2021/2024, Level A and B evidence: ICSI 2013, high quality evidence:
 - ❑ Anticonvulsants (divalproex, valproate, topiramate)
 - ❑ Beta blockers (atenolol, metoprolol, nadolol, propranolol, timolol)
 - ❑ Antidepressants (amitriptyline, venlafaxine)
 - ❑ Angiotensin II receptor blocker (candesartan) ***requires prior authorization***
 - ❑ Injectable CGRP inhibitors (Aimovig[®], Emgality[®], Ajovy[®]) or oral CGRP inhibitors indicated for migraine prevention (Qulipta[™], Nurtec ODT[®]) ***requires prior authorization***
- ❑ **For Ajovy[®] requests for members ≥ 18 years of age:** Member must have tried and failed **ALL** preferred agents, Aimovig[®], Emgality[®], Nurtec ODT[®] and Qulipta[™] **AND** meet all prior authorization criteria for approval of Ajovy[®]
- ❑ Requested medication will **NOT** be used in combination with another injectable CGRP inhibitor (e.g., Aimovig[®], Ajovy[®], Emgality[®], Vyepti[®]), or an oral CGRP inhibitor indicated for migraine prevention (e.g., Nurtec[®] ODT, Qulipta[™])
- ❑ **Requests for concurrent use of Calcitonin Gene-Related Peptide (CGRP) inhibitors with Botox[®] (onabotulinumtoxinA) for migraine headache prevention (if applicable):** Member must meet **ALL** the following criteria (**verified by chart notes and/or pharmacy paid claims**):
 - ❑ Member must have a diagnosis of Chronic or Episodic Migraine Headache and is continuing to experience ≥ 4 migraine headache days per month after receiving therapy with **ALL** the following criteria:
 - ❑ Member must have failed a **2-month** trial of at least one medication from **TWO** different migraine prophylactic classes supported by the American Headache Society/American Academy of Neurology treatment guidelines 2012/2015/2021/2024, Level A and B evidence: ICSI 2013, high quality evidence:
 - ❑ Anticonvulsants (divalproex, valproate, topiramate)
 - ❑ Beta blockers (atenolol, metoprolol, nadolol, propranolol, timolol)
 - ❑ Antidepressants (amitriptyline, venlafaxine)
 - ❑ Angiotensin II receptor blocker (candesartan) ***requires prior authorization***
 - ❑ Member must meet **ONE** of the following:
 - ❑ Member has had an inadequate response to a **2-month** trial with an injectable CGRP inhibitor (e.g., Aimovig[®], Ajovy[®], Emgality[®], Vyepti[®]) or an oral CGRP inhibitor indicated for migraine prevention (e.g., Nurtec[®] ODT, Qulipta[™]) ***requires prior authorization***
 - ❑ Member has had an inadequate response to a **6-month** trial (2 injection cycles) of Botox[®] (onabotulinumtoxinA) ***requires prior authorization***

(Continued on next page)

Episodic Cluster Headaches (Emgality[®] Only) (All applicable boxes below must be met to qualify)

- Member has between one headache every other day and eight headaches per day
- Member must have failed at least a **1-month** trial of at least **ONE generic** standard prophylactic pharmacologic therapy, used to prevent cluster headache and supported by the American Headache Society/American Academy of Neurology treatment guidelines:
 - Suboccipital steroid injection
 - Calcium channel blockers (verapamil)
 - Alkali metal/ Antimanic (lithium)
 - Anticoagulant (warfarin)
 - Anticonvulsants (topiramate)
- Requested medication will **NOT** be used in combination with another injectable CGRP inhibitor (e.g., Aimovig[®], Ajoovy[®], Emgality[®], Vyepti[®]), or an oral CGRP inhibitor indicated for migraine prevention (e.g., Nurtec[®] ODT, Qulipta[™])

*****Use of samples to initiate therapy does not meet step edit/ preauthorization criteria.*****

****Previous therapies will be verified through pharmacy paid claims or submitted chart notes.****